VTGN
Vistagen Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Dec 17 ▼ 3 downgrades
- Jun 30 ▼ Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol f…
- Aug 14 ▼ Vistagen reported Q1 FY2027 net loss of $13.0M ($0.30/share), slight…
- Sep 15 ▼ Short interest jumps 27.3% to 2.71M
- Sep 24 FDA: Vistagen Reports Positive Findings Supporting Fasedienol’s…
- Sep 30 ▼ Short interest jumps 38.6% to 3.75M
- Oct 15 ▲ Short interest falls 34.1% to 2.47M
- Oct 30 ▼ Vistagen Therapeutics cut approximately 31% of its workforce on Octo…
- Nov 9 FDA: Vistagen Provides Regulatory Update Following Productive T…
- Nov 13 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 2 added (0 new), 3 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate −$0.365 → −$0.365 over 90 days. 0 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +0.6% to 2.49M shares. 3.4 days to cover, ≈5.6% of shares.
- TrendDOWNTREND
19% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $459.9K |
| JANE STREET GROUP, LLC | DOUBLED | $163.8K |
| GROUP ONE TRADING LLC | TRIM | $64.3K |
| MORGAN STANLEY | TRIM | $42.00 |
| JPMORGAN CHASE & CO | NEAR_EXIT | $5.00 |
| ROYAL BANK OF CANADA | NEAR_EXIT | Not reported |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $165.1K |
| GROUP ONE TRADING LLC | DOUBLED | $68.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Dec 2025Price is below the lowest target. Median implies +456%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Dec 17, 2025 | William Blair DOWNGRADE | Market Perform |
| Dec 17, 2025 | Maxim Group DOWNGRADE | Hold |
| Dec 17, 2025 | Jefferies DOWNGRADE | Hold |
| Dec 7, 2023 | Jefferies UPGRADE | Buy |
| Nov 14, 2023 | Stifel INITIATE | Buy |
| Sep 5, 2023 | Maxim Group MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Williamson Douglas J Director Jul 29, 2026 | AWARD | 40,826 sh |
Singh Shawn President and CEO Jun 30, 2026 | AWARD | $7.1K |
Tressler Nick B. Chief Financial Officer Jun 30, 2026 | AWARD | $2.2K |
Adler Reid G. Chief Legal Officer Jun 30, 2026 | AWARD | $7.1K |
Angelov Angel S Chief Medical Officer May 18, 2026 | AWARD | 150,000 sh |
Adler Reid G. Chief Legal Officer Apr 7, 2026 | AWARD | 18,753 sh |
Prince Joshua S. Chief Operating Officer Apr 7, 2026 | AWARD | 56,248 sh |
Cote Elissa S. Chief Corp Development Officer Apr 7, 2026 | AWARD | 75,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.36 | -$0.37–-$0.36 | -1.4% | $250.0K |
| Next Q | -$0.36 | -$0.37–-$0.35 | -2.9% | $250.0K |
| Current FY | -$1.48 | -$1.50–-$1.45 | -1.7% | $1.7M |
| Next FY | -$1.54 | -$1.54–-$1.54 | +0.0% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
19 filings · 2 press releases · 1 bullish · 3 bearish · 15 neutral- NEUTRAL SC 13G/ANov 16, 2026
Biotechnology Value Fund L.P. and related entities filed an amended Schedule 13G disclosing a passive stake in Vistagen Therapeutics as of September 30, 2026. The filing shows the group holds 1,690,014 shares (3.7% of outstanding) entirely through T2 warrants exercisable at $8.877 per share.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 13, 2026
Vistagen reported a narrower net loss of $10.7M for Q2 FY2027 (vs. $19.4M a year ago), with EPS of…
The EPS beat and FDA feedback are positive signals, but the cash runway of under one year makes a near-term financing event likely. Monitor for capital raise announcements or partnership deals to…
- NEUTRAL 8-KNov 9, 2026
Vistagen announced FDA feedback from a Type C meeting for its lead candidate fasedienol in social…
The FDA feedback provides a clearer regulatory path for fasedienol, but the company still needs to design, conduct, and fund a Phase 3 study. Watch for the submission of a revised protocol and any…
- NEUTRAL PRESS RELEASENov 9, 2026
Vistagen announced constructive FDA feedback from a Type C meeting on fasedienol for social…
Watch for Vistagen's revised Phase 3 protocol submission and any financing announcements, as the company's $7M market cap suggests limited cash runway to fund a registrational trial.
All VTGN filing & press-release reports (21)
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 13, 2026
- 8-K reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- 8-K reportOct 30, 2026
- 8-K reportOct 9, 2026
- 8-K reportSep 25, 2026
- 8-K reportSep 24, 2026
- PRESS-RELEASE reportSep 24, 2026
- 8-K reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- 8-K reportJul 31, 2026
- 8-K reportJun 30, 2026
- 8-K reportJun 17, 2026
- 8-K reportJun 15, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 9, 2026
- 8-K reportMay 19, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 8, 2026
- 8-K reportApr 13, 2026